Skip to main content

Richard Batycky, PhD

Chief Scientific Officer

Dr. Batycky has over a decade of drug development experience. Prior to co-founding Civitas, Dr. Batycky was the CSO and SVP of research & development at Pulmatrix, Inc., a pharmaceutical company developing novel therapies for treatment and prevention of infectious respiratory disease. Before Pulmatrix, he was VP of research and development for Alkermes, Inc., where he oversaw formulation development, process science, device development and analytical development. There, he was involved in the development of over 10 products across multiple delivery platforms including several approved products (Risperdal® Consta® and Vivitrol®). Prior to Alkermes, Dr. Batycky was an original employee of Advanced Inhalation Research, the original inventor of the enabling delivery platform for CVT-301, until it was acquired by Alkermes. He has served as an assistant professor of chemical engineering at the University of Alberta and he was a post-doc at Penn State University. Dr. Batycky received his PhD from MIT in chemical engineering.


Associated Grants

  • Inhaled Levodopa as a Treatment for Intermittent Motor Fluctuations in Parkinson’s Disease


  • Dry Powder-Based Delivery of Intrapulmonary Levodopa as a Treatment for Motor Fluctuations in Parkinson's Disease


We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.